New website provides comprehensive information and support to people who are
                              trying to conceive

    ROCKLAND, Mass., March 18 /PRNewswire/ -- Serono, Inc. announced today the
launch of seronofertility.com, a newly designed website for people who are
concerned about their fertility health.  Designed specifically for US
residents, the website provides clear, customized information about the causes
and treatment of infertility.
    "We created seronofertility.com to support individuals at every stage of
the patient journey, whether they're just beginning to learn about infertility
or they're undergoing treatment," says Bharat Tewarie, MD, Executive Vice
President, Reproductive Health, Serono, Inc.  "This site is part of Serono,
Inc.'s commitment to continually improve fertility health by developing
patient-friendly products and services."
    Seronofertility.com provides people with a full range of information to
address their various concerns about fertility, including a guide to finding
infertility treatment centers by zip code, questions to ask a doctor about
fertility health, fertility updates by email and information about using
Serono products.  The website also includes downloadable brochures that cover
emotional aspects of infertility, financial issues, male factor infertility
and procedures such as in vitro fertilization.
    "People struggling to conceive can feel isolated and overwhelmed. They
don't know where to turn -- so they all too often suffer in silence," says Dr.
Kaylen Silverberg, Medical Director at Texas Fertility Center in Austin.
"I've found that many patients go online because infertility is such a
personal topic, and they want to seek out information that is specific to
their issues at their convenience.  This website is a good source of
information for anyone interested in learning more about fertility health."
    Infertility is defined as the inability to achieve pregnancy after one
year of regular, unprotected intercourse (six months if the woman is over 35).
It affects about 6.1 million Americans, which represents about 10 percent of
couples in their childbearing years.  About 70% of patients who are treated
succeed in having children.

    About Serono's Commitment to Fertility
    Serono, Inc. is dedicated to providing patient-friendly, innovative
products to help couples build families.  It is the only company to offer a
full portfolio of fertility drugs for every stage of the reproductive cycle
and recombinant versions of two hormones needed to treat infertility.

    About Serono
    Serono, Inc., located in Rockland, MA, is the US affiliate of Serono, a
global biotechnology leader, headquartered in Geneva, Switzerland. The Company
has seven recombinant products, Rebif(R) (interferon beta-1a), Gonal-F(R)
(follitropin alfa for injection), Luveris(R) (lutropin alfa),
Ovidrel(R)/Ovitrelle(R) (choriogonadotropin alfa injection), Serostim(R)
[somatropin (rDNA origin) for injection], Saizen(R) [somatropin (rDNA origin)
for injection] and Zorbtive(TM) [somatropin (rDNA origin) for injection].
(Luveris(R) is not approved in the USA.)1 In addition to being the world
leader in reproductive health, Serono has strong market positions in
neurology, metabolism and growth. The Company's research programs are focused
on growing these businesses and on establishing new therapeutic areas.
Currently, there are approximately 30 ongoing development projects.
    In 2003, Serono achieved worldwide revenues of US$2,018.6 million, and a
net income of US$390.0 million, making it the third largest biotech company in
the world. Its products are sold in over 90 countries. Bearer shares of Serono
S.A., the holding company, are traded on the virt-x (SEO) and its American
Depositary Shares are traded on the New York Stock Exchange (SRA).

    Some of the statements in this press release are forward looking. Such
statements are inherently subject to known and unknown risks, uncertainties
and other factors that may cause actual results, performance or achievements
of Serono S.A. and affiliates to be materially different from those expected
or anticipated in the forward-looking statements. Forward-looking statements
are based on Serono's current expectations and assumptions, which may be
affected by a number of factors, including those discussed in this press
release and more fully described in Serono's Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission on May 21 2002.  These
factors include any failure or delay in Serono's ability to develop new
products, any failure to receive anticipated regulatory approvals, any
problems in commercializing current products as a result of competition or
other factors, our ability to obtain reimbursement coverage for our products,
and government regulations limiting our ability to sell our products. Serono
has no responsibility to update the forward-looking statements contained in
this press release to reflect events or circumstances occurring after the date
of this press release.

    (1) Package inserts for Serono's US marketed products are available at
http://www.seronousa.com or by calling 1-888-275-7376.

     For more information, please contact:
     Serono, Inc., Rockland, MA

     Media Relations:
     Tel. +1 781 681 2340
     Fax: +1 781 681 2935

     Investor Relations:
     Tel. +1 781 681 2552
     Fax: +1 781 681 2912

Link to this page: